{"id":"fremanezumab-prefilled-syringe-ajovy","safety":{"commonSideEffects":[{"rate":"approximately 2-5%","effect":"Injection site reactions"},{"rate":"approximately 5-10%","effect":"Nasopharyngitis"},{"rate":"approximately 3-8%","effect":"Upper respiratory tract infection"},{"rate":"approximately 2-5%","effect":"Headache"},{"rate":"approximately 5-10%","effect":"Antibody formation"}]},"_chembl":{"chemblId":"CHEMBL4297756","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By binding to and neutralizing CGRP, fremanezumab prevents its interaction with CGRP receptors on sensory neurons, thereby reducing migraine frequency and severity. This mechanism has been shown to be effective in both episodic and chronic migraine prevention.","oneSentence":"Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:50.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Migraine prevention in adults (episodic and chronic migraine)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fremanezumab Prefilled Syringe [Ajovy]","genericName":"Fremanezumab Prefilled Syringe [Ajovy]","companyName":"Beth Israel Deaconess Medical Center","companyId":"beth-israel-deaconess-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Migraine prevention in adults (episodic and chronic migraine).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}